SonoScape Medical Croissance future

Future contrôle des critères 5/6

SonoScape Medical devrait augmenter ses bénéfices et son chiffre d'affaires de 55.2% et de 26.7% par an respectivement. Le BPA devrait croître de de 54.9% par an. Le rendement des capitaux propres devrait être 16% dans 3 ans.

Informations clés

55.2%

Taux de croissance des bénéfices

54.9%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	26.5%
Taux de croissance des recettes	26.7%
Rendement futur des capitaux propres	16.0%
Couverture par les analystes	Good
Dernière mise à jour	21 Nov 2024

Mises à jour récentes de la croissance future

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Oct 28

Recent updates

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Oct 28

Investors Appear Satisfied With SonoScape Medical Corp.'s (SZSE:300633) Prospects As Shares Rocket 28%

Oct 21

These 4 Measures Indicate That SonoScape Medical (SZSE:300633) Is Using Debt Reasonably Well

Sep 20

Weak Statutory Earnings May Not Tell The Whole Story For SonoScape Medical (SZSE:300633)

Sep 04

Returns On Capital Signal Tricky Times Ahead For SonoScape Medical (SZSE:300633)

Aug 18

Is SonoScape Medical Corp. (SZSE:300633) Expensive For A Reason? A Look At Its Intrinsic Value

Jul 17

An Intrinsic Calculation For SonoScape Medical Corp. (SZSE:300633) Suggests It's 41% Undervalued

Feb 28

Prévisions de croissance des bénéfices et des revenus

SZSE:300633 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	3,623	805	465	639	11
12/31/2025	2,951	624	304	718	11
12/31/2024	2,088	222	81	324	4
9/30/2024	2,051	243	56	280	N/A
6/30/2024	2,090	352	151	354	N/A
3/31/2024	2,127	416	227	413	N/A
12/31/2023	2,120	454	312	489	N/A
9/30/2023	1,979	445	260	478	N/A
6/30/2023	1,970	468	273	474	N/A
3/31/2023	1,865	457	282	470	N/A
1/1/2023	1,763	370	283	473	N/A
9/30/2022	1,756	353	261	460	N/A
6/30/2022	1,637	313	177	375	N/A
3/31/2022	1,533	262	167	356	N/A
1/1/2022	1,445	247	151	303	N/A
9/30/2021	1,391	66	220	322	N/A
6/30/2021	1,320	38	287	374	N/A
3/31/2021	1,211	-2	208	348	N/A
12/31/2020	1,163	-46	116	271	N/A
9/30/2020	1,176	65	45	193	N/A
6/30/2020	1,195	54	-30	141	N/A
3/31/2020	1,258	81	15	153	N/A
12/31/2019	1,254	102	32	190	N/A
9/30/2019	1,224	146	63	212	N/A
6/30/2019	1,231	207	90	220	N/A
3/31/2019	1,226	244	115	230	N/A
12/31/2018	1,227	253	153	234	N/A
9/30/2018	1,144	246	-1	92	N/A
6/30/2018	1,106	234	N/A	129	N/A
3/31/2018	1,060	201	N/A	99	N/A
12/31/2017	989	190	N/A	139	N/A
9/30/2017	963	192	N/A	175	N/A
6/30/2017	885	171	N/A	146	N/A
3/31/2017	784	134	N/A	157	N/A
12/31/2016	719	130	N/A	137	N/A
3/31/2016	650	103	N/A	94	N/A
12/31/2015	686	106	N/A	56	N/A
12/31/2014	640	132	N/A	114	N/A
12/31/2013	592	71	N/A	90	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 300633 ( 55.2% par an) est supérieure au taux d'épargne ( 2.8% ).

Bénéfices vs marché: Les bénéfices de 300633 ( 55.2% par an) devraient croître plus rapidement que le marché CN ( 26.2% par an).

Croissance élevée des bénéfices: Les bénéfices de 300633 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 300633 ( 26.7% par an) devrait croître plus rapidement que le marché CN ( 13.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 300633 ( 26.7% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 300633 devrait être faible dans 3 ans ( 16 %).

SonoScape Medical Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Price target decreased by 7.8% to CN¥50.15

Price target decreased by 8.0% to CN¥57.34

Price target decreased by 7.4% to CN¥62.43

Price target increased to CN¥71.16

Price target increased to CN¥30.86

Recent updates

Now 22% overvalued after recent price rise

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 23% overvalued

Investors Appear Satisfied With SonoScape Medical Corp.'s (SZSE:300633) Prospects As Shares Rocket 28%

Investor sentiment deteriorates as stock falls 19%

SonoScape Medical Corp. to Report Q3, 2024 Results on Oct 26, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

These 4 Measures Indicate That SonoScape Medical (SZSE:300633) Is Using Debt Reasonably Well

Weak Statutory Earnings May Not Tell The Whole Story For SonoScape Medical (SZSE:300633)

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Returns On Capital Signal Tricky Times Ahead For SonoScape Medical (SZSE:300633)

Is SonoScape Medical Corp. (SZSE:300633) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

SonoScape Medical Corp. to Report First Half, 2024 Results on Aug 29, 2024

Does SonoScape Medical (SZSE:300633) Have A Healthy Balance Sheet?

Dividend increased to CN¥0.32

SonoScape Medical Corp. 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024

Pinning Down SonoScape Medical Corp.'s (SZSE:300633) P/E Is Difficult Right Now

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 7.8% to CN¥50.15

Full year 2023 earnings: EPS misses analyst expectations

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp. to Report Q1, 2024 Results on Apr 27, 2024

We Think SonoScape Medical (SZSE:300633) Can Manage Its Debt With Ease

An Intrinsic Calculation For SonoScape Medical Corp. (SZSE:300633) Suggests It's 41% Undervalued

Less than half of directors are independent

Investor sentiment improves as stock rises 17%

SonoScape Medical Corp. Approves Board Elections

SonoScape Medical Corp. to Report Fiscal Year 2023 Results on Apr 12, 2024

Price target decreased by 8.0% to CN¥57.34

Now 21% undervalued

SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares.

SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.4% to CN¥62.43

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

SonoScape Medical Corp. to Report Q2, 2023 Results on Aug 23, 2023

SonoScape Medical Corp. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 08 June 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

Price target increased to CN¥71.16

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.076 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Sonoscape Medical Corp. Announces Final Dividend on Share A for 2021, Payable on July 15, 2022

SonoScape Medical Corp. Approves 2021 Profit Distribution Plan

SonoScape Medical Corp. Proposes Final Cash Dividend for 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

SonoScape S-Fetus 4.0 Release to Simplify Sonography Process

SonoScape Medical Corp. Receives FDA 510(k) Clearance for HD-550 Endoscopy system

Third quarter 2021 earnings released: EPS CN¥0.076 (vs CN¥0.004 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.085 in 2Q 2020)

SonoScape Obtains CE-Mark for Its Linear Array Echoendoscope EG-UC5T

Price target increased to CN¥30.86

Sonoscape Medical Corp. Proposes Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.02 loss in 1Q 2020)

New 90-day low: CN¥20.36

SonoScape Medical Corp. Announces Executive Election

New 90-day low: CN¥21.50

New 90-day low: CN¥25.16

Third quarter earnings released

SonoScape Medical Corp. announced that it expects to receive CNY 1.2 billion in funding